IL132312A0 - Use of leptin in inhibition of endothelial cell proliferation - Google Patents

Use of leptin in inhibition of endothelial cell proliferation

Info

Publication number
IL132312A0
IL132312A0 IL13231299A IL13231299A IL132312A0 IL 132312 A0 IL132312 A0 IL 132312A0 IL 13231299 A IL13231299 A IL 13231299A IL 13231299 A IL13231299 A IL 13231299A IL 132312 A0 IL132312 A0 IL 132312A0
Authority
IL
Israel
Prior art keywords
leptin
inhibition
cell proliferation
endothelial cell
endothelial
Prior art date
Application number
IL13231299A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13173999A external-priority patent/IL131739A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL13231299A priority Critical patent/IL132312A0/xx
Priority to UA2002042717A priority patent/UA74163C2/uk
Priority to AT00956758T priority patent/ATE449609T1/de
Priority to MXPA02002448A priority patent/MXPA02002448A/es
Priority to EA200200331A priority patent/EA005066B1/ru
Priority to IL14844500A priority patent/IL148445A0/xx
Priority to DE60043391T priority patent/DE60043391D1/de
Priority to ES00956758T priority patent/ES2335569T3/es
Priority to BR0013778-2A priority patent/BR0013778A/pt
Priority to CA2382941A priority patent/CA2382941C/fr
Priority to PCT/IL2000/000525 priority patent/WO2001018040A2/fr
Priority to JP2001522262A priority patent/JP2003508544A/ja
Priority to ARP000104622A priority patent/AR025494A1/es
Priority to AU68620/00A priority patent/AU781390B2/en
Priority to EP00956758A priority patent/EP1210108B1/fr
Priority to EEP200200116A priority patent/EE05262B1/xx
Priority to KR1020027002112A priority patent/KR100683362B1/ko
Priority to CNB00813748XA priority patent/CN1189479C/zh
Publication of IL132312A0 publication Critical patent/IL132312A0/xx
Priority to NO20020920A priority patent/NO325989B1/no
Priority to HK03100442.1A priority patent/HK1048075B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13231299A 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation IL132312A0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IL13231299A IL132312A0 (en) 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation
UA2002042717A UA74163C2 (uk) 1999-09-05 2000-04-09 Застосування лептину для інгібування ангіогенезу, фармацевтична композиція та спосіб інгібування ангіогенезу у ссавців
CNB00813748XA CN1189479C (zh) 1999-09-05 2000-09-04 应用苗条蛋白抑制内皮细胞增殖
BR0013778-2A BR0013778A (pt) 1999-09-05 2000-09-04 Uso de leptina na inibição de proliferação de célula endotelial
JP2001522262A JP2003508544A (ja) 1999-09-05 2000-09-04 内皮細胞増殖の阻害剤におけるレプチンの用途
EA200200331A EA005066B1 (ru) 1999-09-05 2000-09-04 Применение лептина для ингибирования пролиферации эндотелиальных клеток
IL14844500A IL148445A0 (en) 1999-09-05 2000-09-04 Use of leptin in inhibition of endothelial cell proliferation
DE60043391T DE60043391D1 (de) 1999-09-05 2000-09-04 Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen
ES00956758T ES2335569T3 (es) 1999-09-05 2000-09-04 Uso de leptina junto con un inhibidor de vegf y/o un inhibidor de angiogenesis para la inhibicion de la proliferacion de celulas endonteliales.
AT00956758T ATE449609T1 (de) 1999-09-05 2000-09-04 Verwendung von leptin mit einem vegf hemmer und/oder angiogenese hemmer zur hemmung der proliferation endothelialer zellen
CA2382941A CA2382941C (fr) 1999-09-05 2000-09-04 Utilisation de leptine en vue d'empecher la proliferation de la cellule endotheliale
PCT/IL2000/000525 WO2001018040A2 (fr) 1999-09-05 2000-09-04 Utilisation de leptine en vue d'empecher la proliferation de la cellule endotheliale
MXPA02002448A MXPA02002448A (es) 1999-09-05 2000-09-04 Uso de leptina en la inhibicion de la poliferacion de la celula endotelial.
ARP000104622A AR025494A1 (es) 1999-09-05 2000-09-04 Uso de la leptina, homologos de leptina o derivados de leptina opcionalmente junto con un inhibidor de la accion de vegf o de la sintesis del vegf y/o uninhibidor de la angiogenesis, composiciones farmaceuticas que incluyen leptina, metodo para inhibir reversiblemente la proliferacion de dichas celu
AU68620/00A AU781390B2 (en) 1999-09-05 2000-09-04 Use of leptin in inhibition of endothelial cell proliferation
EP00956758A EP1210108B1 (fr) 1999-09-05 2000-09-04 Utilisation de la leptine en combinaison avec un inhibiteur de vegf et/ou un inhibiteur de l'angiogenese pour inhiber la proliferation des cellules endotheliales
EEP200200116A EE05262B1 (et) 1999-09-05 2000-09-04 Leptiini v?i selle homoloogi v?i derivaadi kasutamine, farmatseutiline kompositsioon ja segu
KR1020027002112A KR100683362B1 (ko) 1999-09-05 2000-09-04 내피세포 증식의 저해에서 렙틴의 용도
NO20020920A NO325989B1 (no) 1999-09-05 2002-02-25 Anvendelse av leptin, i kombinasjon med en hemmer av VEGF og/eller angiogenese, for a hemme angiogenese.
HK03100442.1A HK1048075B (zh) 1999-09-05 2003-01-17 應用苗條蛋白抑制內皮細胞增殖

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13173999A IL131739A0 (en) 1999-09-05 1999-09-05 Use of leptin in inhibition of endothelial cell proliferation
IL13231299A IL132312A0 (en) 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation

Publications (1)

Publication Number Publication Date
IL132312A0 true IL132312A0 (en) 2001-03-19

Family

ID=26323878

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13231299A IL132312A0 (en) 1999-09-05 1999-10-10 Use of leptin in inhibition of endothelial cell proliferation

Country Status (19)

Country Link
EP (1) EP1210108B1 (fr)
JP (1) JP2003508544A (fr)
KR (1) KR100683362B1 (fr)
CN (1) CN1189479C (fr)
AR (1) AR025494A1 (fr)
AT (1) ATE449609T1 (fr)
AU (1) AU781390B2 (fr)
BR (1) BR0013778A (fr)
CA (1) CA2382941C (fr)
DE (1) DE60043391D1 (fr)
EA (1) EA005066B1 (fr)
EE (1) EE05262B1 (fr)
ES (1) ES2335569T3 (fr)
HK (1) HK1048075B (fr)
IL (1) IL132312A0 (fr)
MX (1) MXPA02002448A (fr)
NO (1) NO325989B1 (fr)
UA (1) UA74163C2 (fr)
WO (1) WO2001018040A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355237B1 (en) * 1994-09-14 2002-03-12 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US8633250B2 (en) * 2006-01-12 2014-01-21 Musc Foundation For Research Development Cell repair and regeneration by suramin and related polysulfonated napthylureas
EP2455077B1 (fr) * 2009-06-17 2014-06-11 National University Corporation Kumamoto University Agent prophylactique et/ou thérapeutique pour dysménorrhée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4018142B2 (ja) * 1996-01-23 2007-12-05 インデバス ファーマシューティカルズ，インコーポレーテッド 造血発生を刺激するためのｏｂｅｓｅ遺伝子およびその産物の使用方法
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
WO1999059614A1 (fr) * 1998-05-20 1999-11-25 Yale University Modulation de l'angiogenese et de la cicatrisation

Also Published As

Publication number Publication date
DE60043391D1 (de) 2010-01-07
EE05262B1 (et) 2010-02-15
CN1189479C (zh) 2005-02-16
ATE449609T1 (de) 2009-12-15
NO20020920L (no) 2002-05-03
NO325989B1 (no) 2008-09-01
CA2382941C (fr) 2011-08-16
HK1048075B (zh) 2005-07-29
KR100683362B1 (ko) 2007-02-15
EP1210108B1 (fr) 2009-11-25
KR20020040781A (ko) 2002-05-30
ES2335569T3 (es) 2010-03-30
EE200200116A (et) 2003-04-15
MXPA02002448A (es) 2002-07-30
AR025494A1 (es) 2002-11-27
UA74163C2 (uk) 2005-11-15
EA005066B1 (ru) 2004-10-28
HK1048075A1 (en) 2003-03-21
AU781390B2 (en) 2005-05-19
NO20020920D0 (no) 2002-02-25
WO2001018040A3 (fr) 2001-06-14
BR0013778A (pt) 2002-05-14
AU6862000A (en) 2001-04-10
JP2003508544A (ja) 2003-03-04
EA200200331A1 (ru) 2002-08-29
CA2382941A1 (fr) 2001-03-15
CN1377277A (zh) 2002-10-30
EP1210108A2 (fr) 2002-06-05
WO2001018040A2 (fr) 2001-03-15

Similar Documents

Publication Publication Date Title
PT1526132E (pt) Derivados de oxazolidinona substituídos e sua utilização enquanto inibidores do factor xa
IL144214A0 (en) Benzoheterocycles and their use as mek inhibitors
IL148698A0 (en) INHIBITORS OF FACTOR Xa
HK1045299B (zh) 細胞增殖抑制劑
IL149374A0 (en) New use and novel n-azabicyclo-amide derivatives
IL144668A0 (en) The use of 4-h-1-benzopyran-4- one derivatives as inhibitors of smooth muscle cell proliferation
IL190220A0 (en) Novel composition and use
HUP0200549A3 (en) Apomorphine and sildenafil composition and their use
AU1939801A (en) In situ bioreactors and methods of use thereof
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
IL143987A0 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
EG22491A (en) Rest-breaking composition and use thereof
IL132312A0 (en) Use of leptin in inhibition of endothelial cell proliferation
IL148445A0 (en) Use of leptin in inhibition of endothelial cell proliferation
IL131739A0 (en) Use of leptin in inhibition of endothelial cell proliferation
HK1054385A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
GB9911606D0 (en) Composition and use
AU4025100A (en) Immortal microvascular endothelial cells and uses thereof
GB9929581D0 (en) Comjpositions and their use
AU2045601A (en) Methods and agents for the inhibition of smooth muscle cell proliferation
SI1150996T1 (sl) Novi amidinobenzilaminski derivati in njihova uporaba kot trombinski inhibitorji
SI1233964T1 (en) New use and novel n-azabicyclo-amide derivatives
SI1163208T1 (en) Caspase inhibitors and uses thereof